{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:39:26Z","timestamp":1794893966952,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Fund of Anhui Institute of translational medicine","award":["2023zhyx-B10"],"award-info":[{"award-number":["2023zhyx-B10"]}]},{"name":"Outstanding Project of Jianghuai Talent Training Program in Anhui Province","award":["Outstanding Project of Jianghuai Talent Training Program in Anhui Province"],"award-info":[{"award-number":["Outstanding Project of Jianghuai Talent Training Program in Anhui Province"]}]},{"name":"the Key Scientific Research Foundation of the Education Department of Anhui Province","award":["2023AH053163"],"award-info":[{"award-number":["2023AH053163"]}]},{"name":"National Natural Science Foundation Incubation Program of The Second Affiliated Hospital of Anhui Medical University","award":["2023GQFY01"],"award-info":[{"award-number":["2023GQFY01"]}]},{"name":"Clinical Medicine project of Anhui Medical University","award":["Clinical Medicine project of Anhui Medical University"],"award-info":[{"award-number":["Clinical Medicine project of Anhui Medical University"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Primary hypertrophic osteoarthropathy (PHO) is a rare genetic disorder classified into clinical subtypes and genetic subtypes. Previous clinical studies have primarily focused on case reports and family analyses, largely characterizing the genetic subtypes. However, there remains a long-standing gap in understanding the characteristics of the different clinical subtypes of PHO. This study aimed to determine the distribution of the three clinical subtypes of PHO and compare their clinical characteristics using a large global sample.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic literature search was conducted in multiple databases to categorize cases into complete form (CO), incomplete form (IN), and fruste form (FR). Statistical analyses were performed to assess clinical differences in a retrospective study design.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Males predominated across all subtypes, whereas females were most prevalent in IN patients (51.1%). IN patients had the highest family history rate (62.1%). Age at onset peaked in adolescence for CO and FR patients, while IN patients exhibited bimodal peaks in early childhood and adolescence. Congenital diseases were more frequent in IN patients (7.8%, <jats:italic>P<\/jats:italic>\u2009=\u20090.021), while CO patients had a higher prevalence of digestive system diseases (12.2%, <jats:italic>P<\/jats:italic>\u2009=\u20090.007). Urinary prostaglandin E2 (PGE2) and PGE Metabolite (PGEM) were consistently elevated in CO and FR patients. In IN patients, urinary PGE2 levels were also increased, but the urinary PGEM levels showed equal proportions of elevation and reduction. Genetic analysis revealed that solute carrier organic anion transporter family member 2A1 (SLCO2A1) mutations were predominant in CO (95 cases, 73.1%) and FR (22 cases, 57.9%) patients, whereas hydroxyprostaglandin dehydrogenase (HPGD) mutations were most frequently associated with IN (25 cases, 73.5%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The three clinical subtypes of PHO exhibited distinct characteristics with no clear correlation between clinical and genetic subtypes. These findings highlighted the clinical significance of PHO typing and provided valuable insights for diagnosis, differential diagnosis and subtype-specific management strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03722-3","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T04:50:56Z","timestamp":1744951856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Distinct features of three clinical subtypes in 533 patients with primary hypertrophic osteoarthropathy"],"prefix":"10.1186","volume":"20","author":[{"given":"Xilei","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongzhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8544-2460","authenticated-orcid":false,"given":"Xiaodan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-9004","authenticated-orcid":false,"given":"Zhenhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"issue":"6","key":"3722_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1399-0004.2005.00533.x","volume":"68","author":"M Castori","year":"2005","unstructured":"Castori M, Sinibaldi L, Mingarelli R, et al. Pachydermoperiostosis: an update. Clin Genet. 2005;68(6):477\u201386.","journal-title":"Clin Genet"},{"key":"3722_CR2","first-page":"1820","volume":"43","author":"A Touraine","year":"1935","unstructured":"Touraine A, Solente G, Gole L. Un syndrome osteodermopathique: La pachydermie plicaturee avec pachyperiostose des extremites. Presse Med. 1935;43:1820\u20134.","journal-title":"Presse Med"},{"issue":"3","key":"3722_CR3","doi-asserted-by":"publisher","first-page":"101507","DOI":"10.1016\/j.berh.2020.101507","volume":"34","author":"M Martinez-Lavin","year":"2020","unstructured":"Martinez-Lavin M. Hypertrophic osteoarthropathy. Best Pract Res Clin Rheumatol. 2020;34(3):101507.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"13","key":"3722_CR4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMicm2309119","volume":"390","author":"M Lucas Rocha","year":"2024","unstructured":"Lucas Rocha M, Silvestre-Teixeira V. Secondary hypertrophic osteoarthropathy. N Engl J Med. 2024;390(13):1218.","journal-title":"N Engl J Med"},{"issue":"6","key":"3722_CR5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/ng.153","volume":"40","author":"S Uppal","year":"2008","unstructured":"Uppal S, Diggle CP, Carr IM, et al. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet. 2008;40(6):789\u201393.","journal-title":"Nat Genet"},{"issue":"4","key":"3722_CR6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/humu.22042","volume":"33","author":"W Seifert","year":"2012","unstructured":"Seifert W, Kuhnisch J, Tuysuz B, Specker C, Brouwers A, Horn D. Mutations in the prostaglandin transporter encoding gene SLCO2A1 cause primary hypertrophic osteoarthropathy and isolated digital clubbing. Hum Mutat. 2012;33(4):660\u20134.","journal-title":"Hum Mutat"},{"issue":"6","key":"3722_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1600-0625.2011.01248.x","volume":"20","author":"C Bergmann","year":"2011","unstructured":"Bergmann C, Wobser M, Morbach H, et al. Primary hypertrophic osteoarthropathy with digital clubbing and palmoplantar hyperhidrosis caused by 15-PGHD\/HPGD loss-of-function mutations. Exp Dermatol. 2011;20(6):531\u20133.","journal-title":"Exp Dermatol"},{"issue":"3","key":"3722_CR8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/jbmr.4488","volume":"37","author":"Q Pang","year":"2022","unstructured":"Pang Q, Xu Y, Huang L, et al. Bone geometry, density, microstructure, and Biomechanical properties in the distal tibia in patients with primary hypertrophic osteoarthropathy assessed by Second-Generation High-Resolution peripheral quantitative computed tomography. J Bone Min Res. 2022;37(3):484\u201393.","journal-title":"J Bone Min Res"},{"issue":"3","key":"3722_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2165\/00128071-200102030-00002","volume":"2","author":"AM Layton","year":"2001","unstructured":"Layton AM. Optimal management of acne to prevent scarring and psychological sequelae. Am J Clin Dermatol. 2001;2(3):135\u201341.","journal-title":"Am J Clin Dermatol"},{"key":"3722_CR10","doi-asserted-by":"publisher","first-page":"1235040","DOI":"10.3389\/fendo.2023.1235040","volume":"14","author":"Q Lu","year":"2023","unstructured":"Lu Q, Xu Y, Zhang Z, Li S, Zhang Z. Primary hypertrophic osteoarthropathy: genetics, clinical features and management. Front Endocrinol (Lausanne). 2023;14:1235040.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"3722_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ajhg.2011.11.019","volume":"90","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, Xia W, He J, et al. Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy. Am J Hum Genet. 2012;90(1):125\u201332.","journal-title":"Am J Hum Genet"},{"issue":"8","key":"3722_CR12","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/jbmr.4310","volume":"36","author":"Y Xu","year":"2021","unstructured":"Xu Y, Zhang Z, Yue H, Li S, Zhang Z. Monoallelic mutations in SLCO2A1 cause autosomal dominant primary hypertrophic osteoarthropathy. J Bone Min Res. 2021;36(8):1459\u201368.","journal-title":"J Bone Min Res"},{"key":"3722_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/CCID.S389766","volume":"16","author":"YJ Chen","year":"2023","unstructured":"Chen YJ, Li L. A complete form of Pachydermoperiostosis accompanied by a pituitary microadenoma. Clin Cosmet Investig Dermatol. 2023;16:47\u201352.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"3722_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.abd.2019.04.009","volume":"95","author":"MLP Honorio","year":"2020","unstructured":"Honorio MLP, Bezerra GH, Costa V. Complete form of Pachydermoperiostosis. Bras Dermatol. 2020;95(1):98\u2013101.","journal-title":"Bras Dermatol"},{"issue":"6","key":"3722_CR15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.4103\/ijdvl.IJDVL_911_17","volume":"85","author":"X Li","year":"2019","unstructured":"Li X, Hao D, Li-Ling J, Jiang X. Complete form of Pachydermoperiostosis with cutis verticis gyrata resulting from the SLCO2A1 gene mutation. Indian J Dermatol Venereol Leprol. 2019;85(6):681.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"9","key":"3722_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/qjmed\/hcac147","volume":"115","author":"K Ikeda","year":"2022","unstructured":"Ikeda K, Miyamori D, Hirabayashi R, Ito M. Pachydermoperiostosis QJM. 2022;115(9):611\u20132.","journal-title":"Pachydermoperiostosis QJM"},{"issue":"9","key":"3722_CR17","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.7150\/ijbs.71261","volume":"18","author":"Q Lu","year":"2022","unstructured":"Lu Q, Xu Y, Li S, Zhang Z, Sheng J, Zhang Z. Clinical and biochemical characteristics of 12 Chinese primary hypertrophic osteoarthropathy patients with HPGD mutations. Int J Biol Sci. 2022;18(9):3908\u201317.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"3722_CR18","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/bjd.12790","volume":"170","author":"H Niizeki","year":"2014","unstructured":"Niizeki H, Shiohama A, Sasaki T, et al. The novel SLCO2A1 heterozygous missense mutation p.E427K and nonsense mutation p.R603* in a female patient with Pachydermoperiostosis with an atypical phenotype. Br J Dermatol. 2014;170(5):1187\u20139.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3722_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11684-013-0246-6","volume":"7","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013;7(1):60\u20134.","journal-title":"Front Med"},{"issue":"8","key":"3722_CR20","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/humu.22111","volume":"33","author":"CP Diggle","year":"2012","unstructured":"Diggle CP, Parry DA, Logan CV, et al. Prostaglandin transporter mutations cause Pachydermoperiostosis with myelofibrosis. Hum Mutat. 2012;33(8):1175\u201381.","journal-title":"Hum Mutat"},{"issue":"3","key":"3722_CR21","doi-asserted-by":"publisher","first-page":"e63446","DOI":"10.1002\/ajmg.a.63446","volume":"194","author":"TN Kimball","year":"2024","unstructured":"Kimball TN, Rivero-Garcia P, Barrera-Godinez A, Dominguez-Cherit J. Genotype and phenotype characterization of primary hypertrophic osteoarthropathy type 2 and chronic enteropathy associated with SLCO2A1: report of two cases and literature review. Am J Med Genet A. 2024;194(3):e63446.","journal-title":"Am J Med Genet A"},{"key":"3722_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jot.2018.10.001","volume":"18","author":"L Yuan","year":"2019","unstructured":"Yuan L, Liao RX, Lin YY, et al. Safety and efficacy of cyclooxygenase-2 Inhibition for treatment of primary hypertrophic osteoarthropathy: A single-arm intervention trial. J Orthop Translat. 2019;18:109\u201318.","journal-title":"J Orthop Translat"},{"issue":"2","key":"3722_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.rdc.2013.02.008","volume":"39","author":"C Pineda","year":"2013","unstructured":"Pineda C, Martinez-Lavin M. Hypertrophic osteoarthropathy: what a rheumatologist should know about this uncommon condition. Rheum Dis Clin North Am. 2013;39(2):383\u2013400.","journal-title":"Rheum Dis Clin North Am"},{"issue":"4 Suppl","key":"3722_CR24","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1542\/peds.113.S3.957","volume":"113","author":"RL Brent","year":"2004","unstructured":"Brent RL. Environmental causes of human congenital malformations: the pediatrician\u2019s role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors [J]. Pediatrics. 2004;113(4 Suppl):957\u201368.","journal-title":"Pediatrics"},{"issue":"28","key":"3722_CR25","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.3346\/jkms.2021.36.e183","volume":"36","author":"KS Lee","year":"2021","unstructured":"Lee KS, Choi YJ, Cho J, et al. Environmental and genetic risk factors of congenital anomalies: an umbrella review of systematic reviews and meta-analyses [J]. J Korean Med Sci. 2021;36(28):e183.","journal-title":"J Korean Med Sci"},{"issue":"6","key":"3722_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.semarthrit.2008.01.018","volume":"38","author":"MB Santiago","year":"2009","unstructured":"Santiago MB, Lima I, Feitosa AC, Braz Ade S, Miranda LG. Pseudoclubbing: is it different from clubbing? [J]. Semin Arthritis Rheum. 2009;38(6):452\u20137.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"3722_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4081\/reumatismo.2018.1049","volume":"70","author":"MS Chimenti","year":"2018","unstructured":"Chimenti MS, Di Stefani A, Conigliaro P, et al. Histopathology of the skin in rheumatic diseases [J]. Reumatismo. 2018;70(3):187\u201398.","journal-title":"Reumatismo"},{"issue":"5","key":"3722_CR28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.beem.2018.05.005","volume":"32","author":"NM Appelman-Dijkstra","year":"2018","unstructured":"Appelman-Dijkstra NM, Papapoulos SE. Paget\u2019s disease of bone [J]. Best Pract Res Clin Endocrinol Metab. 2018;32(5):657\u201368.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"3722_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1148\/radiol.2331030326","volume":"233","author":"MD Murphey","year":"2004","unstructured":"Murphey MD, Jelinek JS, Temple HT, Flemming DJ, Gannon FH. Imaging of periosteal osteosarcoma: radiologic-pathologic comparison [J]. Radiology. 2004;233(1):129\u201338.","journal-title":"Radiology"},{"issue":"5","key":"3722_CR30","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1210\/jc.2012-3568","volume":"98","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, He JW, Fu WZ, Zhang CQ, Zhang ZL. Mutations in the SLCO2A1 gene and primary hypertrophic osteoarthropathy: a clinical and biochemical characterization [J]. J Clin Endocrinol Metab. 2013;98(5):923\u201333.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"3722_CR31","first-page":"554","volume":"51","author":"N Xu","year":"2022","unstructured":"Xu N, Fu W, Zhang N. The value of platelet to hemoglobin ratio in judging the disease activity of rheumatoid arthritis [J]. J China Med Univ. 2022;51(6):554\u20137.","journal-title":"J China Med Univ"},{"issue":"6","key":"3722_CR32","first-page":"317","volume":"115","author":"C Bray","year":"2016","unstructured":"Bray C, Bell LN, Liang H, et al. Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine [J]. WMJ. 2016;115(6):317\u201321.","journal-title":"WMJ"},{"issue":"1","key":"3722_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2012.07.008","volume":"68","author":"T Sasaki","year":"2012","unstructured":"Sasaki T, Niizeki H, Shimizu A, et al. Identification of mutations in the prostaglandin transporter gene SLCO2A1 and its phenotype-genotype correlation in Japanese patients with Pachydermoperiostosis [J]. J Dermatol Sci. 2012;68(1):36\u201344.","journal-title":"J Dermatol Sci"},{"issue":"5","key":"3722_CR34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3346\/jkms.2016.31.5.735","volume":"31","author":"S Lee","year":"2016","unstructured":"Lee S, Park SY, Kwon HJ, Lee CH, Kim OH, Rhee Y. Identification of the mutations in the prostaglandin transporter gene, SLCO2A1 and clinical characterization in Korean patients with Pachydermoperiostosis [J]. J Korean Med Sci. 2016;31(5):735\u201342.","journal-title":"J Korean Med Sci"},{"issue":"7","key":"3722_CR35","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/1346-8138.12869","volume":"42","author":"K Tanese","year":"2015","unstructured":"Tanese K, Niizeki H, Seki A, et al. Pathological characterization of pachydermia in Pachydermoperiostosis [J]. J Dermatol. 2015;42(7):710\u20134.","journal-title":"J Dermatol"},{"issue":"11","key":"3722_CR36","doi-asserted-by":"publisher","first-page":"e1005581","DOI":"10.1371\/journal.pgen.1005581","volume":"11","author":"J Umeno","year":"2015","unstructured":"Umeno J, Hisamatsu T, Esaki M, et al. A hereditary enteropathy caused by mutations in the SLCO2A1 gene, encoding a prostaglandin transporter [J]. PLoS Genet. 2015;11(11):e1005581.","journal-title":"PLoS Genet"},{"issue":"6","key":"3722_CR37","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.cgh.2015.10.022","volume":"14","author":"E Washio","year":"2016","unstructured":"Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized, placebo-controlled trial [J]. Clin Gastroenterol Hepatol. 2016;14(6):809\u201315.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03722-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03722-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03722-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T04:50:57Z","timestamp":1744951857000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03722-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3722"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03722-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}